Skip to main content

Table 1 Patients’ baseline demographics and characteristics

From: Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study

 

All

IFX

TCZ

ABT

p Valuea

Number of patients

209

140

38

31

–

Female sex, n (%)

172 (82.3 %)

113 (80.7 %)

34 (89.5 %)

25 (80.6 %)

0.46626

Age, yr, median (IQR)

59.0 (47.0–66.0)

57.5 (46.0–64.3)

56.0 (44.8–64.0)

67.0 (62.0–74.0)

0.00003

Disease duration, yr, median (IQR)

3.3 (1.1–10.5)

3.3 (1.1–10.3)

4.2 (1.5–9.4)

2.4 (0.5–14.5)

0.86013

Concomitant drug use

 Steroid use, n (%)

80 (38.3 %)

56 (40.0 %)

14 (36.8 %)

10 (32.3 %)

0.75247

 Steroid dose, mg/day, median (IQR)

0 (0–5.0)

0 (0–5.0)

0 (0–3.0)

0 (0–2.5)

0.34861

 MTX dose, mg/week, median (IQR)

8.0 (8.0–8.0)

8.0 (8.0–10.0)

8.0 (6.0–8.0)

8.0 (6.0–8.0)

0.00271

 csDMARD useb (except MTX), n (%)

29 (13.9 %)

20 (14.3 %)

5 (13.2 %)

4 (12.9 %)

1.00000

Serological markers

 RF positivity, n (%)

154 (74.8 %)c

103 (74.1 %)d

28 (73.7 %)

23 (79.3 %)e

0.88544

 RF titer, median (IQR)

55 (15–115)c

53 (14–115)d

54 (17–115)

77 (22–106)e

0.94307

 ACPA positivity, n (%)

85 (85.9 %)f

51 (85.0 %)g

13 (100 %)h

21 (80.8 %)i

0.31205

 ACPA titer, median (IQR)

85.6 (12.8–100)f

100 (13.3–100)g

83 (42.9–100)h

62.1 (9.8–100)i

0.89773

TJC28, median (IQR)

6.0 (2.0–8.0)

6.0 (2.0–8.3)

6.0 (3.0–8.8)

6.0 (3.0–8.0)

0.68798

SJC28, median (IQR)

6.0 (3.0–11.0)

7.0 (3.8–11.0)

6.0 (4.0–8.0)

5.0 (3.0–8.0)

0.46376

PtGA, mm, median (IQR)

53 (28–72)

52 (27–72)

52 (31–67)

63 (41–73)

0.34811

PhGA, mm, median (IQR)

43 (30–60)

43 (29–63)

43 (33–60)

45 (31–56)

0.91700

CRP, mg/dl, median (IQR)

0.9 (0.4–2.4)

1.0 (0.4–2.6)

0.6 (0.2–2.0)

0.8 (0.4–2.0)

0.19092

ESR, mm/h, median (IQR)

42 (25–69)

45 (28–69)

37 (22–60)

37 (23–74)

0.27517

DAS28-ESR, median (IQR)

5.3 (4.4–6.1)

5.3 (4.4–6.2)

5.1 (4.5–5.8)

5.5 (4.7–6.1)

0.65899

SDAI score, median (IQR)

22.5 (16.2–31.3)

23.2 (15.6–32.2)

22.1 (16.8–28.5)

23.3 (16.8–31.5)

0.96973

CDAI score, median (IQR)

21.7 (14.9–28.9)

21.9 (14.6–29.6)

20.6 (16.4–26.0)

22.8 (15.1–28.5)

0.99430

  1. Abbreviations: IFX infliximab, TCZ tocilizumab, ABT abatacept, IQR interquartile range, MTX methotrexate, csDMARD conventional synthetic disease-modifying antirheumatic drug, RF rheumatoid factor, ACPA anticyclic citrullinated peptide antibodies, TJC28 28 tender joint count, SJC28 28 swollen joint count, PtGA patient global assessment, PhGA physician global assessment, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity score in 28 joints, SDAI simplified disease activity index, CDAI clinical disease activity index
  2. aKruskal-Wallis test was used for numerical variables to evaluate the differences between the three drug groups. For categorical variables, Fisher’s exact test was used. p < 0.05 was considered statistically significant
  3. bIncluding salazosulfapyridine, bucillamine, tacrolimus, d-penicillamine, actarit, and azathioprine
  4. cAvailable for 206 of 209
  5. dAvailable for 139 of 140
  6. eAvailable for 29 of 31
  7. fAvailable for 99 of 209
  8. gAvailable for 60 of 140
  9. hAvailable for 13 of 38
  10. iAvailable for 26 of 31
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us